Glenn Pierce
InvestorInvestment Committee Co-Chair at Pathway to Cures · Director at Voyager Therapeutics, Inc.
Boston, Massachusetts, United States
Find your path to Glenn
624 people in our graph share verified history with Glenn — schools, employers, funds. One of them is your warm intro.
Lisa PurcellunlockedGlenn: together at Third Rock Ventures (2024–2025)
×7Glenn: together at Third Rock Ventures
×3Glenn: together at Case Western Reserve University
Glenn: together at Bayer HealthCare
About
Pierce is an independent consultant and entrepreneur-in-residence at Third Rock Ventures with 30 years of biotech R&D experience. He retired from Biogen in 2014 as SVP of Hematology, Cell and Gene Therapies.
Director at Voyager Therapeutics, Inc.
Intro paths
→
In turn, Glenn can intro founders to Voyager Therapeutics, Inc.'s investors below.
Voyager Therapeutics, Inc.'s investors · 3
Experience
- Typewriter, Frontera, Be Bio (to 2026), Metagenomi (to 2026), hC Bio (to 2025), Decibel (to 2023)Scientific Advisory Boardcurrent2020 — presentBoston, San Francisco
- Global Blood Therap (2016-22), Voyager Therapeutics (2017-), World Federation of Hemophilia 2015-26Directorcurrent2016 — present
- Self EmployedVolunteer, Consultant, Advisorcurrent2015 — present
- World Federation of Hemophilia / Fédération mondiale de l'hémophilieVice President, Medical2018 — 2026Greater Montreal Metropolitan Area
- Third Rock VenturesEntrepreneur In Residence2016 — 2025San Francisco Bay Area
- Voyager Therapeutics, Inc.Interim CSO2021 — 2022Cambridge, Massachusetts, United States
- Ambys MedicinesInterim CMO2018 — 2022San Francisco Bay Area
- Hiatus-2014 — 2016
- BiogenSVP, Hematology, Cell and Gene Therapies2014
- BiogenSVP, Global Medical Affairs and Chief Medical Officer, Hemophilia Therapeutic Area2012 — 2014
- BiogenSVP and CMO Hemophilia Business2009 — 2012
- Bayer HealthCareScientific Head, US Research Center/VP Applied Research2005 — 2009
- AvigenVice President Research/Development2002 — 2005
- Selective GeneticsVice President, Therapeutic Product Development1994 — 2002
- AmgenAssoc Med Director1988 — 1994
Skills & more
Clinical Development99Immunology66Pharmacology38Hematology43Polymers2Partnerships4Biotechnology68Lifesciences7Pharmaceutical Industry39Technology Transfer17Oncology13Drug Discovery22
+8 more
Clinical TrialsLipidTissueBiopharmaceuticalsDrug DevelopmentFDACommercializationMolecular BiologyFrom Glenn's professional profile.
Colleagues at Pathway to Cures
Amy L. Dunn
Chair, Medical and Scientific Advisory Council (MASAC) for NBDF at Pathway to Cures
Beth Whitehouse
NBDF Senior Vice President for Advancement at Pathway to Cures
Brian Andrew
Investment Committee Chair at Pathway to Cures
Christine Brennan
Investment Committee Member at Pathway to Cures
Geeta Vemuri
Managing Partner, Founder at Agent Capital
Gilbert C. White
P2C Board Vice Chair & Secretary at Pathway to Cures
Gilbert C. White, II
P2C Board Vice Chair & Secretary at Pathway to Cures
Haiyan Jiang
Scientific Advisory Group Member at Pathway to Cures
Frequently asked questions
- Who is Glenn Pierce?
- Pierce is an independent consultant and entrepreneur-in-residence at Third Rock Ventures with 30 years of biotech R&D experience. He retired from Biogen in 2014 as SVP of Hematology, Cell and Gene Therapies.
- Where does Glenn Pierce work?
- Glenn Pierce is Investment Committee Co-Chair at Pathway to Cures.
- Where did Glenn Pierce go to school?
- Glenn Pierce studied at Washington University School of Medicine in St. Louis (Lab Medicine Residency and Hematology Fellowship/Post-doc); Case Western Reserve University School of Medicine (Internship, Internal Medicine); Case Western Reserve University School of Medicine (MD, PhD).
Same school
Also attended Washington University School of Medicine in St. Louis27
Reid HuberPartner at Third Rock VenturesDavid CohnInterim Chief Executive Officer and Chief Medical Officer at Oncology VenturesBen ScruggsPartner at Hatteras Venture PartnersDaguang WangManaging Director at Yonjin Venture LLCDave VreelandSenior Managing Partner at Caduceus Capital PartnersDana WattPartner at Breakout Ventures
+ 21 more
Also attended Case Western Reserve University School of Medicine22
Richard RansohoffVenture Partner at Third Rock VenturesTodd PonskyChief Innovation Officer at Flare Capital PartnersTarek El-SawyVenture Partner at RaivenKingsley R. ChinManaging Partner at KIC VenturesSteven SchachterAdvisor, Medtech at Iaso VenturesGuy Fish, MDStrategic Advisor at Fletcher Spaght, Inc.
+ 16 more
Also attended Case Western Reserve University134
Will BruneSenior Associate at Mutual Capital PartnersKT MooreAdvisor at Clear VenturesPete KoomenGeneral Partner at Y CombinatorAsheem ChandnaPartner at Greylock focused on enterprise, cybersecurity, and infrastructure softwareMatt SteinChief Information Officer at Flare Capital PartnersKaren SpilizewskiBiomedical engineer helping accelerate life science technologies from development into the marketplace
+ 128 more
Shared employers
Also worked at Third Rock Ventures91
Lisa PurcellInvestor at Third Rock VenturesPaul MeloneInvestor at Third Rock VenturesLee VeneziaInvestor at Third Rock VenturesKevin MunnellyInvestor at Third Rock VenturesAmanda ChanInvestor at Third Rock VenturesJigar RaythathaInvestor at Third Rock Ventures
+ 85 more
Also worked at Ambys Medicines3
Also worked at Biogen98
Jigar RaythathaInvestor at Third Rock VenturesRichard RansohoffVenture Partner at Third Rock VenturesIsaiah Baril-DoreInvestor at Index VenturesRoy LobbVenture Partner at Advent Life SciencesSun AltbachSenior Scientific Advisor at BOLD LongevityJohn McCabePortfolio Company CFO & COO at Longwood Fund
+ 92 more
Also worked at Bayer HealthCare149
Vincent RoseInvestment Manager at Burda Principal InvestmentsBenjamin BrockwellVenture Partner at Copper Sky CapitalAxel BouchonVenture Partner at ARCH Venture PartnersVincent RulandEntrepreneur-in-Residence at Versant VenturesAtsushi ShimadaSenior Principal at AN Venture PartnersMelike Abacioglu GunesVP of Marketing at Asymmetric Capital Partners
+ 143 more














































